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A New Branching Point for Renal Denervation?*Neal N. Sawlani, MD, Deepak L. Bhatt, MD, MPHSEE PAGE 1766R enal artery denervation as a potential treat-ment for resistant hypertension and othercardiovascular conditions has generated
immense interest among the medical community (1).
To date, much of renal denervation and its potential
mode of efﬁcacy has been a “black box,” with great
uncertainty around the optimal technique (2) or
whether the procedure even works at all (3). Several
reasons for the variability in response to renal artery
denervation in humans have been posed, particularly
limitations with the anatomic targets used for radio-
frequency ablation in clinical trials. Thus, recently
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have garnered signiﬁcant attention (4). It is possible
that improvements in catheter electrodes and the
technique of staggered proximal renal artery ablation
could help unify the observed phenotypic response in
humans.In this issue of the Journal, Mahfoud et al. (5)
present a carefully done study that identiﬁes differ-
ences in renal norepinephrine tissue content and
renal cortical axon density on the basis of renal
artery lesion placement. The investigators used
multielectrode catheters to apply radiofrequency to
the renal artery endoluminal surface in young and
healthy porcine models. They independently varied
the number of cycles of treatment and the location
of the lesions to include the main renal artery, the
renal artery branches, or both. Importantly, re-
ductions in norepinephrine content paralleled the
loss of cortical sympathetic nerves. This ﬁnding
further corroborates the pathophysiological mecha-
nism underlying catheter-based renal denervation
for cardiovascular conditions (6). It is also worth
noting that the porcine models undergoing treat-
ment were compared with tissue samples from naive
swine that went untreated. A more rigorous method
of comparison would have been to compare contra-
lateral cortical concentrations within each animal
with the control swine. However, the magnitude of
response in the treated kidneys was sufﬁciently
large, and the analogous effect on norepinephrine
and nerve density suggests that the methodology
should sufﬁce.
The investigators report multiple key ﬁndings.
First, increasing the number of lesions from 4 to 8
in the main renal artery did not produce signiﬁ-
cant incremental gains; however, increasing the
number of lesions to 12 led to further reductions in
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The distal segment of a renal artery has more adjacent nerves, though at lower density. A circumferential arc of treatment can be delivered to
achieve threshold effect. Adapted with permission from Sakakura et al. (8) and Tzafriri et al. (4).
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1777norepinephrine and axonal concentrations. This sug-
gests limited utility of a small increase in the number
of radiofrequency doses and, possibly, a threshold ef-
fect beyond a larger number of applied cycles (4).
These results may be consistent with ﬁndings from
the multicenter SYMPLICTY HTN-3 (Renal Denerva-
tion in Patients With Uncontrolled Hypertension)
trial, in which a single-electrode catheter was used (3).
In this new analysis, the number of ablation attempts
correlated with ofﬁce systolic blood pressure reduc-
tion, and the greatest marginal beneﬁt was observed
after 14 ablation attempts (7). Taken together, these
ﬁndings support the need for more complete circum-
ferential ablation patterns, with little beneﬁt above
initial incomplete ablation lines.
Second, the study results demonstrate the greatest
effect on norepinephrine concentration and ganglion
density in the porcine models that were treated in the
branch vessel in addition to the main renal artery.
The investigators postulate that the shorter distance
of nerve endings to the arterial lumen in the distal
segment of the renal artery may account for the
improved treatment efﬁcacy (8). With the inclusion of
branch vessel ablation, there was no observed beneﬁt
to increasing the number of proximal lesions. It ap-
pears that the addition of distal lesion targets may be
the most efﬁcient approach for improving success in
renal denervation, despite fewer nerves surrounding
the distal vessel (Figure 1). This signiﬁcant ﬁnding
provides a physiological basis for some of the vari-
ability seen in human trials of renal denervation. It
emphasizes the importance of pre-clinical research,
and ideally, investigations of this sort should havebeen done before initial clinical trials involving
humans.
Last, we should be encouraged by the consistent
safety proﬁle of catheter-based renal artery dener-
vation. The investigators did not identify any signif-
icant perfusion or angiographic defects. Surrounding
tissue largely healed, as anticipated, and there were
no unexpected changes to the arterial wall from
radiofrequency ablation.
However, there are a few caveats to be consid-
ered with the study’s ﬁndings. Experiments with
young nonhypertensive swine are unlikely to
mimic the noncompliant and atherosclerotic renal
arteries of the older human subjects enrolled in
clinical trials of resistant hypertension (3). If the
results of the study represent optimal outcomes
from healthy tissue, it is unclear if the beneﬁt of
branch vessel ablation will extend the same rewards
in diseased segments. After all, the limited efﬁcacy
of proximal renal artery ablation in the study fails
to explain the positive results of prior human
studies in which 4 to 6 proximal ablation lines were
created (9). It is also important to see whether the
surrogate markers of norepinephrine and ganglion
concentration will translate to sustained blood
pressure reductions in humans. Histological speci-
mens at 6 months conﬁrm peak nerve damage
within 30 days and nerve regeneration as early as
60 days after ablation (10). Ambulatory blood pres-
sure monitoring in human subjects has shown no
further reduction in blood pressure at 1 year (11,12).
Ideally, before the clinical adoption, long-term
norepinephrine and nerve axon results would be
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1778obtained to quantify the recovery rate of the renal
arterial wall.
As is often the case with modern interven-
tional technologies, the experience in catheter-based
renal denervation will continue to undergo bouts
of rapid transformation. Ongoing studies in humans
are currently using new approaches with multi-
electrode catheters, incorporating this ongoing acc-
rual of knowledge (NCT02439775, NCT02439749, and
NCT02392351). With new methodological standards
(13) and novel pre-clinical studies, catheter-basedrenal denervation is poised to undergo signiﬁcant
innovation in device application. Renal denervation
appears to have reached a new branch point in its
development.
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